Clinical trials come up short again for Alphamab Oncology
The Chinese pharmaceutical firm has suffered its second clinical setback in a matter of weeks, after its U.S. partner halted trials of a sarcoma drug Key Takeaways: Alphamab Oncology could…
Recent Articles
RELATED ARTICLES
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK -
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
- Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
